

## **US immigration order strikes against biotech**

To the Editor:

We the undersigned, founders and leaders of biotech companies, write to express our deep concern and opposition to the executive order signed by President Donald Trump on January 27, 2017, barring the entry of citizens from seven countries into the United States<sup>1</sup>.

The United States is the world's greatest developer of medicines and new inventions to ameliorate and cure intractable diseases, a status achieved through massive investment in private and public companies, academia and R&D. Most importantly, our success has been founded on the creativity and dedication of our most precious resource—our people.

Our people include researchers, clinicians, entrepreneurs and business executives from all over the world. They are colleagues in our laboratories, management teams and boardrooms. They discover and develop therapies that drive US biomedical innovation and deliver new medicines to patients, not only in America, but also across the globe. And they start companies that drive the economic growth and employment provided by biotech. Many of our colleagues from abroad ultimately become Americans, all to the great benefit of the United States. Indeed, a study found that in 2014, 52% of the 69,000 biomedical researchers in the United States were foreign-born<sup>2</sup>.

The biopharma industry originated in America and is dominated by American companies. US companies employ tenfold more people than European companies. Over the past decade, a total of \$98.4 billion was invested in US emerging therapeutic companies through venture capital, follow-on public offerings and initial public offerings. US companies spent over \$138 billion on upfront payments for in-licensing assets or acquiring global R&D-stage emerging companies. Larger US biopharma companies spent \$161.7 billion over the past ten years on market-stage acquisitions.

The United States has led the world in medicine production for decades, not only because of its ability to finance drug discovery, but also because, more than any other country, the United States represents opportunity regardless of borders, gender, race, sexual orientation or political cast. This has enabled our industry to attract the best talent, wherever it is found. This aspect of our industry is a core reason the United States has built its unique strength in biopharmaceuticals.

At a stroke, the new administration has compromised years of investment in this national treasure. Our colleagues who are here on visas or are in global outposts are now fearful and uncertain of their status. Scientists based in other countries and employed by our companies are afraid to come to the United States or are canceling trips. The parents and families of immigrants who live and work in the United States are reluctant to attempt to travel to and from the United States.

Though the ban from the Trump administration is aimed at seven countries, our global employees interpret the underlying message as, "America is no longer welcoming of any immigrants, whatsoever." They fear similar orders could be issued for other countries at a moment's notice. They fear being stigmatized and discriminated against, simply because of their religion, irrespective of the nation they come from. Several among us have heard from employees about their deportation fears, how they do not feel comfortable leaving the country on business or how they now feel cut off from their family abroad.

Every nation has the right to determine who comes across its borders. Every nation needs to be vigilant in defending itself against and hunting down terrorists. The actions taken by the Trump administration, however, were poorly conceived and implemented; they have raised deep fears and concerns across the biotech industry, in which diversity and the free flow of ideas and people have created an American powerhouse of medicine.

If this misguided policy is not reversed, America is at risk of losing its leadership position in one of its most important sectors, one that will shape the world in the twenty-first century. Indeed, it will harm an industry dominated by smaller companies and startups, the very kind of industry the administration has said it wants to support. It will slow the fight against the many diseases that afflict us, as well as carry negative economic consequences for the United States.

America must remain the world's greatest engine of innovation, as well as the beacon of liberty it has been for more than 200 years. The two are inextricably intertwined.

(On February 2, 2017, the United States District Court Western District of Washington at Seattle issued a temporary restraining order against the executive order that suspends its enforcement nationwide. The President has stated he will seek to overturn the ruling, but the restraining order remains in force while under appeal to the US Court of Appeals for the 9th Circuit by the Department of Justice. As of 7pm on February 6, the federal appeals court has not yet ruled<sup>3</sup>.)

*Jeremy M Levin*<sup>1</sup>, *Steven H Holtzman*<sup>2</sup>, *John Maraganore*<sup>3</sup>, *Paul J Hastings*<sup>4</sup>, *Ron Cohen*<sup>5</sup>, *Bassil I Dahiyat*<sup>6</sup>,  
*Julian Adams*<sup>7</sup>, *Chris Adams*<sup>8</sup>, *Brett Ahrens*<sup>9</sup>, *Jeff Albers*<sup>10</sup>, *Mara G Aspinall*<sup>11</sup>, *James Audia*<sup>12</sup>, *Martin Babler*<sup>13</sup>,  
*Peter Barrett*<sup>14</sup>, *Zoe Barry*<sup>15</sup>, *Nessan Bermingham*<sup>16</sup>, *Stephen Bloch*<sup>17</sup>, *Robert I Blum*<sup>18</sup>, *Paul B Bolono*<sup>19</sup>, *Michael  
W Bonney*<sup>20</sup>, *Bruce Booth*<sup>21</sup>, *Daniel M Bradbury*<sup>22</sup>, *Steven K Brauer*<sup>23</sup>, *Brook Byers*<sup>24</sup>, *Pablo J Cagnoni*<sup>25</sup>, *Brian  
M Cali*<sup>26</sup>, *Isaac Ciechanover*<sup>27</sup>, *Chip Clark*<sup>28</sup>, *Michael D Clayman*<sup>29</sup>, *Jeff L Cleland*<sup>30</sup>, *Paula Cobb*<sup>31</sup>, *Ron  
Cooper*<sup>32</sup>, *Mark G Currie*<sup>33</sup>, *John Diekman*<sup>34</sup>, *Eric I Dobmeier*<sup>35</sup>, *Doug Doerfler*<sup>36</sup>, *Deborah Dunsire*<sup>37</sup>, *Matthew  
During*<sup>38</sup>, *Jens W Eckstein*<sup>39</sup>, *Eric Elenko*<sup>40</sup>, *Neil A Exter*<sup>41</sup>, *Jonathan J Fleming*<sup>42</sup>, *Gregory J Flesher*<sup>43</sup>, *Jean-  
Francois Formela*<sup>44</sup>, *Robert Forrester*<sup>45</sup>, *Cedric Francois*<sup>46</sup>, *Heather Franklin*<sup>47</sup>, *Mason W Freeman*<sup>48</sup>, *Leonard  
Patrick Gage*<sup>49</sup>, *Nicolas Galakatos*<sup>50</sup>, *James A Geraghty*<sup>51</sup>, *Simba Gill*<sup>52</sup>, *David V Goeddel*<sup>53</sup>, *Mark A Goldsmith*<sup>54</sup>,  
*Maxine Gowen*<sup>55</sup>, *Tom Graney*<sup>56</sup>, *David Grayzel*<sup>57</sup>, *Barry Greene*<sup>58</sup>, *Paul Grint*<sup>59</sup>, *J C Gutierrez-Ramos*<sup>60</sup>, *Tuan  
Ha-Ngoc*<sup>61</sup>, *Bill Haney*<sup>62</sup>, *Faheem Hasnain*<sup>63</sup>, *Yujiro Steve Hata*<sup>64</sup>, *Peter Hecht*<sup>65</sup>, *Rich Heyman*<sup>66</sup>, *Herve  
Hoppenot*<sup>67</sup>, *H Robert Horvitz*<sup>68</sup>, *Thomas E Hughes*<sup>69</sup>, *Wende S Hutton*<sup>70</sup>, *Annalisa Jenkins*<sup>71</sup>, *Rachel King*<sup>72</sup>,  
*Vanessa King*<sup>73</sup>, *Nina Kjellson*<sup>74</sup>, *Gerhard Koenig*<sup>75</sup>, *Scott Koenig*<sup>76</sup>, *Peter Kolchinsky*<sup>77</sup>, *Paul Laikind*<sup>78</sup>, *Robert  
(Bob) Langer*<sup>79</sup>, *John J Lee*<sup>80</sup>, *Jonathan S Leff*<sup>81</sup>, *Nick Leschly*<sup>82</sup>, *Mark Levin*<sup>83</sup>, *Arnold Levine*<sup>84</sup>, *Alan Levy*<sup>85</sup>,  
*David Liu*<sup>86</sup>, *Harvey F Lodish*<sup>87</sup>, *Uri Lopatin*<sup>88</sup>, *Ted W Love*<sup>89</sup>, *Guy Macdonald*<sup>90</sup>, *Gail J Maderis*<sup>91</sup>, *Ankit  
Mahadevia*<sup>92</sup>, *Nagesh K Mahanthappa*<sup>93</sup>, *Joel F Martin*<sup>94</sup>, *W Eddie Martucci*<sup>95</sup>, *James McArthur*<sup>96</sup>, *Corey M  
McCann*<sup>97</sup>, *Sean A McCarthy*<sup>98</sup>, *C Geoffrey McDonough*<sup>99</sup>, *John Mendlein*<sup>100</sup>, *Diego Miralles*<sup>101</sup>, *Kenneth I  
Moch*<sup>102</sup>, *Bob Moore*<sup>103</sup>, *Andrew G Myers*<sup>104</sup>, *Michael A Narachi*<sup>105</sup>, *Amir Nashat*<sup>106</sup>, *William J Newell*<sup>107</sup>, *Bernat  
Olle*<sup>108</sup>, *John E Osborn*<sup>109</sup>, *Julia C Owens*<sup>110</sup>, *Atul Pande*<sup>111</sup>, *H Stewart Parker*<sup>112</sup>, *Kush M Parmar*<sup>113</sup>, *Matthew R  
Patterson*<sup>114</sup>, *Steve M Paul*<sup>115</sup>, *Rob Perez*<sup>116</sup>, *Matthew Perry*<sup>117</sup>, *Cary G Pfeffer*<sup>118</sup>, *Mike Powell*<sup>119</sup>, *Dennis J  
Purcell*<sup>120</sup>, *Amit Rakhit*<sup>121</sup>, *Kartick Ramamoorthi*<sup>122</sup>, *William Rastetter*<sup>123</sup>, *Adrian (Ad) Rawcliffe*<sup>124</sup>, *Laurence E  
Reid*<sup>125</sup>, *Jason P Rhodes*<sup>126</sup>, *William J Rieflin*<sup>127</sup>, *Chad Robins*<sup>128</sup>, *Scott M Rocklage*<sup>129</sup>, *Michael Rosenblatt*<sup>130</sup>,  
*Jonathan G Rosin*<sup>131</sup>, *William J Rutter*<sup>132</sup>, *Saurabh Saha*<sup>133</sup>, *Camille Samuels*<sup>134</sup>, *Vicki L Sato*<sup>135</sup>, *George  
Scangos*<sup>136</sup>, *John A Scarlett*<sup>137</sup>, *Stuart L Schreiber*<sup>138</sup>, *Andrew Schwab*<sup>139</sup>, *Paul Sekhri*<sup>140</sup>, *Thomas Shenk*<sup>141</sup>, *Clay  
B Siegall*<sup>142</sup>, *Nick J Simon*<sup>143</sup>, *Nancy Simonian*<sup>144</sup>, *Jeff Stein*<sup>145</sup>, *Michael Su*<sup>146</sup>, *Mary T Szela*<sup>147</sup>, *Henri Termeer*<sup>148</sup>,  
*Nancy A Thornberry*<sup>149</sup>, *Martin Tolar*<sup>150</sup>, *Richard Ulevitch*<sup>151</sup>, *Akshay K Vaishnav*<sup>152</sup>, *Anne VanLent*<sup>153</sup>, *George P  
Vlasuk*<sup>154</sup>, *Michel Vounatsos*<sup>155</sup>, *Samuel G Waksal*<sup>156</sup>, *Neil Warma*<sup>157</sup>, *Ryan J Watts*<sup>158</sup>, *Yaron Werber*<sup>159</sup>,  
*Christoph Westphal*<sup>160</sup>, *Wendell Wierenga*<sup>161</sup>, *Doug E Williams*<sup>162</sup>, *Lewis (Rusty) Williams*<sup>163</sup>, *Kleanthis G  
Xanthopoulos*<sup>164</sup>, *Daphne Zohar*<sup>165</sup> & *Sandford (Sandy) Zweifach*<sup>166</sup>

<sup>1</sup>Ovid Therapeutics Inc., New York, New York, USA. <sup>2</sup>Decibel Therapeutics, Cambridge, Massachusetts, USA.

<sup>3</sup>Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>4</sup>OncoMed Pharmaceuticals, Redwood City, California, USA. <sup>5</sup>Acorda Therapeutics Inc., Ardsley, New York, USA. <sup>6</sup>Xencor, Monrovia, California, USA. <sup>7</sup>Clal Biotechnology Industries, Cambridge, Massachusetts, USA. <sup>8</sup>Cydan Development Inc., Cambridge, Massachusetts, USA. <sup>9</sup>Caanan Partners, Menlo Park, California, USA. <sup>10</sup>Blueprint Medicines, Cambridge, Massachusetts, USA. <sup>11</sup>Health Catalysts, Tuscon, Arizona, USA. <sup>12</sup>Constellation Pharmaceuticals, Inc., Cambridge, Massachusetts,

USA. <sup>13</sup>Principia Biopharma, South San Francisco, California, USA. <sup>14</sup>Atlas Venture, Cambridge, Massachusetts, USA. <sup>15</sup>ZappRx, Boston, Massachusetts, USA. <sup>16</sup>Intellia Therapeutics, Cambridge, Massachusetts, USA. <sup>17</sup>Caanan Partners, Westport, Connecticut, USA. <sup>18</sup>Cytokinetics, Inc., South San Francisco, California, USA. <sup>19</sup>Wave Life Sciences, Cambridge, Massachusetts, USA. <sup>20</sup>Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>21</sup>Atlas Venture, Cambridge, Massachusetts, USA. <sup>22</sup>Amylin Pharmaceuticals, San Diego, California, USA. <sup>23</sup>Salus Discovery LLC, San Diego, California, USA. <sup>24</sup>Investor, Menlo Park, California, USA. <sup>25</sup>Tizona Therapeutics, Inc., South San Francisco, California, USA. <sup>26</sup>Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>27</sup>Atara Bio, South San Francisco, California, USA. <sup>28</sup>Genocea Biosciences, Inc., Cambridge, Massachusetts, USA. <sup>29</sup>Flexion Therapeutics, Burlington, Massachusetts, USA. <sup>30</sup>Graybug Vision, Redwood City, California, USA. <sup>31</sup>Decibel Therapeutics, Cambridge, Massachusetts, USA. <sup>32</sup>Albireo Pharma Inc., Boston, Massachusetts, USA. <sup>33</sup>Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>34</sup>5AM Ventures, San Francisco, California, USA. <sup>35</sup>Seattle Genetics, Bothell, Washington, USA. <sup>36</sup>MaxCyte, Inc., Gaithersburg, Maryland, USA. <sup>37</sup>Southern Cross Biotech Consulting, Waltham, Massachusetts, USA. <sup>38</sup>Ovid Therapeutics Inc., New York, New York, USA. <sup>39</sup>SR One, Conshohocken, Pennsylvania, USA. <sup>40</sup>PureTech Health, Boston, Massachusetts, USA. <sup>41</sup>Third Rock Ventures, Boston, Massachusetts, USA. <sup>42</sup>Q-State Biosciences, Cambridge, Massachusetts, USA. <sup>43</sup>OticPharma Inc., Irvine, California, USA. <sup>44</sup>Atlas Venture, Cambridge, Massachusetts, USA. <sup>45</sup>Verastem Inc., Needham, Massachusetts, USA. <sup>46</sup>Apellis Pharmaceuticals, Crestwood, Kentucky, USA. <sup>47</sup>Blaze Bioscience Inc., Seattle, Washington, USA. <sup>48</sup>5AM Ventures, Boston, Massachusetts, USA. <sup>49</sup>Tetraphase, Watertown, Massachusetts, USA. <sup>50</sup>Clarus, Cambridge, Massachusetts, USA. <sup>51</sup>Juniper Pharmaceuticals, Boston, Massachusetts, USA. <sup>52</sup>Evelo Biosciences, Cambridge, Massachusetts, USA. <sup>53</sup>The Column Group, San Francisco, California, USA. <sup>54</sup>Revolution Medicines, Inc., Redwood City, California, USA. <sup>55</sup>Trevena Inc., King of Prussia, Pennsylvania, USA. <sup>56</sup>Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>57</sup>Atlas Venture, Cambridge, Massachusetts, USA. <sup>58</sup>Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>59</sup>Regulus Therapeutics, San Diego, California, USA. <sup>60</sup>Synlogic, Cambridge, Massachusetts, USA. <sup>61</sup>KEW, Inc., Cambridge, Massachusetts, USA. <sup>62</sup>Dragonfly Therapeutics, Inc., Cambridge, Massachusetts, USA. <sup>63</sup>FSG Biotech, San Diego, California, USA. <sup>64</sup>IDEAYA Biosciences, South San Francisco, California, USA. <sup>65</sup>Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>66</sup>Metacrine, Inc., San Diego, California, USA. <sup>67</sup>Incyte, Wilmington, Delaware, USA. <sup>68</sup>Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. <sup>69</sup>Zafgen, Inc., Boston, Massachusetts, USA. <sup>70</sup>Caanan Partners, Menlo Park, California, USA. <sup>71</sup>Dimension Therapeutics, Cambridge, Massachusetts, USA. <sup>72</sup>GlycoMimetics, Inc., Rockville, Maryland, USA. <sup>73</sup>Luc Therapeutics, Inc., Cambridge, Massachusetts, USA. <sup>74</sup>Caanan Partners, Menlo Park, California, USA. <sup>75</sup>Quartet Medicine, Cambridge, Massachusetts, USA. <sup>76</sup>MacroGenics, Inc., Rockville, Maryland, USA. <sup>77</sup>RA Capital Management, LLC, Boston, Massachusetts, USA. <sup>78</sup>ViaCyte, Inc., San Diego, California, USA. <sup>79</sup>Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. <sup>80</sup>Decibel Therapeutics, Cambridge, Massachusetts, USA. <sup>81</sup>Deerfield Management, New York, New York, USA. <sup>82</sup>Bluebird Bio, Cambridge, Massachusetts, USA. <sup>83</sup>Third Rock Ventures, Boston, Massachusetts, USA. <sup>84</sup>Institute for Advanced Study, Princeton, New Jersey, USA. <sup>85</sup>Chrono Therapeutics, Hayward, California, USA. <sup>86</sup>Editas Medicine, Cambridge, Massachusetts, USA. <sup>87</sup>Whitehead Institute MIT, Cambridge, Massachusetts, USA. <sup>88</sup>Assembly Biosciences, Carmel, Indiana, USA. <sup>89</sup>Global Blood

Therapeutics, South San Francisco, California, USA. <sup>90</sup>Tetraphase, Watertown, Massachusetts, USA. <sup>91</sup>Antiva Biosciences, Inc., South San Francisco, California, USA. <sup>92</sup>Spero Therapeutics, Cambridge, Massachusetts, USA. <sup>93</sup>Scholar Rock, Cambridge, Massachusetts, USA. <sup>94</sup>Dauntless Pharmaceuticals, Inc., San Diego, California, USA. <sup>95</sup>Akili Interactive, Boston, Massachusetts, USA. <sup>96</sup>Imara, Cambridge, Massachusetts, USA. <sup>97</sup>Pear Therapeutics, Boston, Massachusetts, USA. <sup>98</sup>CytomX, South San Francisco, California, USA. <sup>99</sup>Sobi, Waltham, Massachusetts, USA. <sup>100</sup>aTyr Pharma, San Diego, California, USA. <sup>101</sup>Adaptive Biotechnologies, Seattle, Washington, USA. <sup>102</sup>Cognition Therapeutics, Inc., Pittsburgh, Pennsylvania, USA. <sup>103</sup>Alta Partners, San Francisco, California, USA. <sup>104</sup>Harvard University, Cambridge, Massachusetts, USA. <sup>105</sup>Orexigen Therapeutics, La Jolla, California, USA. <sup>106</sup>Polaris Partners, Boston, Massachusetts, USA. <sup>107</sup>Sutro Biopharma, Inc., South San Francisco, California, USA. <sup>108</sup>Vedanta Biosciences, Inc., Cambridge, Massachusetts, USA. <sup>109</sup>Egalet, Wayne, Pennsylvania, USA. <sup>110</sup>Millendo Therapeutics, Inc., Ann Arbor, Michigan, USA. <sup>111</sup>Verity BioConsulting, San Diego, California, USA. <sup>112</sup>Parker BioConsulting, Seattle, Washington, USA. <sup>113</sup>5AM Ventures, Boston, Massachusetts, USA. <sup>114</sup>Audentes Therapeutics, Inc., San Francisco, California, USA. <sup>115</sup>Voyager Therapeutics, Inc., Cambridge, Massachusetts, USA. <sup>116</sup>Life Science Cares, Boston, Massachusetts, USA. <sup>117</sup>BVF Partners, LP, San Francisco, California, USA. <sup>118</sup>Third Rock Ventures, Boston, Massachusetts, USA. <sup>119</sup>Sofinnova Ventures, Menlo Park, California, USA. <sup>120</sup>Aisling Capital LLC, New York, New York, USA. <sup>121</sup>Ovid Therapeutics Inc., New York, New York, USA. <sup>122</sup>Encoded Genomics, South San Francisco, California, USA. <sup>123</sup>Neurocrine Biosciences Inc., San Diego, California, USA. <sup>124</sup>Adaptimmune, Philadelphia, Pennsylvania, USA. <sup>125</sup>Warp Drive Bio, Cambridge, Massachusetts, USA. <sup>126</sup>Atlas Venture, Cambridge, Massachusetts, USA. <sup>127</sup>NGM Biopharmaceuticals, Inc., South San Francisco, California, USA. <sup>128</sup>Adaptive Biotechnologies, Seattle, Washington, USA. <sup>129</sup>5AM Ventures, San Francisco, California, USA. <sup>130</sup>Flagship Pioneering, Cambridge, Massachusetts, USA. <sup>131</sup>Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>132</sup>Synergenics, LLC, San Francisco, California, USA. <sup>133</sup>Delinia, Cambridge, Massachusetts, USA. <sup>134</sup>Venrock, Palo Alto, California, USA. <sup>135</sup>Harvard Business School, Cambridge, Massachusetts, USA. <sup>136</sup>Vir Bio, San Francisco, California, USA. <sup>137</sup>Geron Corporation, Menlo Park, California, USA. <sup>138</sup>Broad Institute, Cambridge, Massachusetts, USA. <sup>139</sup>5AM Ventures, San Francisco, California, USA. <sup>140</sup>Lycera Corporation, New York, New York, USA. <sup>141</sup>Lewis Thomas Laboratory, Princeton University, Princeton, New Jersey, USA. <sup>142</sup>Seattle Genetics, Inc., Bothell, Washington, USA. <sup>143</sup>Clarus Ventures LLC, South San Francisco, California, USA. <sup>144</sup>Syros Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>145</sup>Cidara Therapeutics, San Diego, California, USA. <sup>146</sup>Decibel Therapeutics, Cambridge, Massachusetts, USA. <sup>147</sup>Novelion Therapeutics, Vancouver, British Columbia, Canada. <sup>148</sup>Formerly of Genzyme, Cambridge, Massachusetts, USA. <sup>149</sup>Kallyope, New York, New York, USA. <sup>150</sup>Alzheon, Framingham, Massachusetts, USA. <sup>151</sup>5AM Ventures, La Jolla, California, USA. <sup>152</sup>Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA. <sup>153</sup>AMV Advisors, Princeton, New Jersey, USA. <sup>154</sup>Navitor Pharmaceuticals, Inc., Cambridge, Massachusetts, USA. <sup>155</sup>Biogen, Cambridge, Massachusetts, USA. <sup>156</sup>MeiraGTx, New York, New York, USA. <sup>157</sup>Opexa Therapeutics, Inc., The Woodlands, Texas, USA. <sup>158</sup>Denali Therapeutics, Inc., South San Francisco, California, USA. <sup>159</sup>Ovid Therapeutics, Inc., New York, New York, USA. <sup>160</sup>Flex Pharma, Boston, Massachusetts, USA. <sup>161</sup>Crinetics Pharmaceuticals, San Diego, California, USA. <sup>162</sup>Codiak BioSciences, Cambridge, Massachusetts, USA. <sup>163</sup>Five Prime Therapeutics, Inc., South San Francisco, California, USA. <sup>164</sup>Cerus, La Jolla, California, USA.

<sup>165</sup>*PureTech Health, Boston, Massachusetts, USA.* <sup>166</sup>*Nuvelution Pharmaceuticals, Inc., South San Francisco, California, USA.*

1. The White House. Executive Order: Protecting the Nation from Foreign Terrorist Entry into the United States, Jan. 27, 2017.
2. Heggeness, M.L., Gunsalus, K.T.W., Pacas, J. & McDowell, G. *Nature* **541**, 21–23 (2017).
3. 17-35105 [State of Washington & State of Minnesota v. Trump](#). WD Wash. 2:17-cv-141, Judge Robart.